US84833T1034

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 28, 2025 08:00 ET  | Source: Spero Therapeutics, Inc. CAMBRIDGE, Mass., Nov. 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics,…

1 week ago

PIVOT-PO Phase 3 Data Show Tebipenem HBrs Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared…

2 months ago